Details for Patent: 8,871,761
✉ Email this page to a colleague
Which drugs does patent 8,871,761 protect, and when does it expire?
Patent 8,871,761 protects VEOZAH and is included in one NDA.
This patent has twenty-five patent family members in twenty countries.
Summary for Patent: 8,871,761
| Title: | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
| Abstract: | The present invention is directed to novel compounds of formula I |
| Inventor(s): | Hoveyda Hamid R., Roy Marie-Odile, Fraser Graeme Lovat, Dutheuil Guillaume |
| Assignee: | Euroscreen S.A. |
| Application Number: | US13627091 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 8,871,761
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | VEOZAH | fezolinetant | TABLET;ORAL | 216578-001 | May 12, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,871,761
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011234398 | ⤷ Try a Trial | |||
| Brazil | 112012025101 | ⤷ Try a Trial | |||
| Canada | 2793313 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
